

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

ID8

RRID:CVCL_IU14

Type: Cell Line

Proper Citation

Millipore Cat# SCC145, RRID:CVCL_IU14

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_IU14

Proper Citation: Millipore Cat# SCC145, RRID:CVCL_IU14

Description: Cell line ID8 is a Spontaneously immortalized cell line with a species of origin *Mus musculus* (Mouse)

Sex: Female

Defining Citation: [PMID:10753190](#), [PMID:16886597](#), [PMID:18036641](#), [PMID:27235858](#)

Comments: Characteristics: Physiologically and biologically closely resembles human epithelial ovarian cancer.

Category: Spontaneously immortalized cell line

Organism: *Mus musculus* (Mouse)

Name: ID8

Synonyms: ID8/MOSEC

Cross References: CLS:305305, Millipore:SCC145, PRIDE:PXD013062, Ubigen:YC-C103, Wikidata:Q54897292

ID: CVCL_IU14

Vendor: Millipore

Catalog Number: SCC145

Record Creation Time: 20220427T220629+0000

Record Last Update: 20260829T234312+0000

Ratings and Alerts

No rating or validation information has been found for ID8.

No alerts have been found for ID8.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Huang Q, et al. (2026) Cutibacterium acnes-Derived Extracellular Vesicles Promote Epithelial Ovarian Cancer Progression by Activating the KEAP1-NRF2 Antioxidant Pathway to Suppress Ferroptosis. Microbial biotechnology, 19(5), e70373.

Chan V, et al. (2026) Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis. Advanced healthcare materials, e71424.

Feng L, et al. (2026) Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy. Advanced science (Weinheim, Baden-Wurtemberg, Germany), 13(19), e21279.

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. Science advances, 12(16), eaeb0855.

Zhao Y, et al. (2026) Physiological respiration pressure-driven piezocatalytic therapy for malignant ascites with a gold-core magnified mesoporous piezoelectric nanoplatform. Biomaterials, 333, 124233.

Aobulikasimu N, et al. (2026) Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. Materials today. Bio, 37, 102924.

Tian M, et al. (2026) Combination of Tripterygium glycosides and Lactobacillus paracasei sensitises epithelial ovarian cancer to cisplatin via downregulating Keap1-Nrf2-GPX4 signalling pathway. Cellular & molecular biology letters, 31(1).

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. Cell reports methods, 101515.

Lujano-Olazaba O, et al. (2026) RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. Cell reports, 45(7), 117650.

Lin C, et al. (2026) Enterolactone and THBS1-3TSR synergistically inhibit ovarian cancer and suppress angiogenesis in the tumour microenvironment. *British journal of pharmacology*, 183(11), 2837.

Jiang Y, et al. (2026) *Malassezia restricta*-Derived Extracellular Vesicles Drive Ovarian Cancer Progression Through JAK2/STAT3-Mediated M2 Macrophage Polarisation. *Microbial biotechnology*, 19(6), e70396.

Yamamoto TM, et al. (2026) Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. *Molecular cancer therapeutics*, 25(7), 1130.

Duan W, et al. (2026) Salmonella Bacteria Membrane-Fusion Paclitaxel Loaded Liposomes for Enhanced Therapy of Intraperitoneal Metastatic Ovarian Cancer. *Advanced healthcare materials*, 15(15), e05868.

Lee W, et al. (2025) Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. *Cancer cell*, 43(1), 69.

Xu S, et al. (2025) Dexmedetomidine alleviates the pro-tumor activity of perioperative stress in tumor-bearing mice: an alternative approach of psycho-physiological intervention. *World journal of surgical oncology*, 23(1), 103.

Yoshida Y, et al. (2025) Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense. *Theranostics*, 15(2), 340.

Pakhira S, et al. (2025) Altered fatty acid oxidation via CPT1A promotes epithelial-to-mesenchymal transition in ovarian cancer. *The FEBS journal*.

Guo Z, et al. (2025) Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment. *EBioMedicine*, 119, 105879.

Zheng Y, et al. (2025) IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF- κ B/CXCL1 axis in ovarian cancer. *Cell death & disease*, 17(1), 95.

Cudmore AO, et al. (2025) Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer. *Molecular cancer therapeutics*, 24(10), 1626.